Study identifier:D6402C00014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Open-label Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of a Single Dose of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
Healthy Volunteer
Phase 1
Yes
balcinrenone/dapagliflozin
All
10
Interventional
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: balcinrenone/dapagliflozin To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants | - |